Krystal Biotech clinical trials we track

Check company identity source

Phase 3 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: To evaluate the safety and tolerability of KB803. Measure: To evaluate the effect of ophthalmic KB803 versus placebo on frequency of corneal. abrasion symptoms.. After: Measure: To evaluate the safety and tolerability of KB803. Measure: To evaluate the effect of ophthalmic KB803 on frequency of corneal abrasion symptoms..

Planned enrollment increased by 4 participants

Before: 16 participants (planned). After: 20 participants (planned).

Primary completion date changed

Before: Mar 2026. After: Dec 2026.

Check registry source